B

BL PharmTech Corp
KOSDAQ:065170

Watchlist Manager
BL PharmTech Corp
KOSDAQ:065170
Watchlist
Price: 564 KRW Market Closed
Market Cap: 15B KRW

Intrinsic Value

The intrinsic value of one BL PharmTech Corp stock under the Base Case scenario is 524.07 KRW. Compared to the current market price of 564 KRW, BL PharmTech Corp is Overvalued by 7%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

Intrinsic Value
524.07 KRW
Overvaluation 7%
Intrinsic Value
Price
B
Worst Case
Base Case
Best Case

Valuation History
BL PharmTech Corp

What is Valuation History?
Ask AI Assistant
What other research platforms think about BL PharmTech Corp?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is BL PharmTech Corp valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for BL PharmTech Corp.

Explain Valuation
Compare BL PharmTech Corp to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about BL PharmTech Corp?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
BL PharmTech Corp

Current Assets 7.6B
Cash & Short-Term Investments 3.8B
Receivables 2.9B
Other Current Assets 884.1m
Non-Current Assets 26.9B
Long-Term Investments 18B
PP&E 3.9B
Intangibles 91.7m
Other Non-Current Assets 5B
Current Liabilities 10.6B
Accounts Payable 272m
Accrued Liabilities 74.1m
Short-Term Debt 1B
Other Current Liabilities 9.3B
Non-Current Liabilities 1.4B
Long-Term Debt 352.5m
Other Non-Current Liabilities 1.1B
Efficiency

Free Cash Flow Analysis
BL PharmTech Corp

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
BL PharmTech Corp

Revenue
8.6B KRW
Cost of Revenue
-3.2B KRW
Gross Profit
5.4B KRW
Operating Expenses
-9.9B KRW
Operating Income
-4.5B KRW
Other Expenses
-1.2B KRW
Net Income
-5.7B KRW
Fundamental Scores

Profitability Score
Profitability Due Diligence

BL PharmTech Corp's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Sustainable 3Y Average Gross Margin
Gross Margin is Increasing
Declining ROE
22/100
Profitability
Score

BL PharmTech Corp's profitability score is 22/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

BL PharmTech Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Low D/E
Negative Net Debt
Long-Term Solvency
Short-Term Solvency
42/100
Solvency
Score

BL PharmTech Corp's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
BL PharmTech Corp

There are no price targets for BL PharmTech Corp.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for BL PharmTech Corp is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one BL PharmTech Corp stock?

The intrinsic value of one BL PharmTech Corp stock under the Base Case scenario is 524.07 KRW.

Is BL PharmTech Corp stock undervalued or overvalued?

Compared to the current market price of 564 KRW, BL PharmTech Corp is Overvalued by 7%.

Back to Top